Putting the "Bio" Back Into Biomarkers: Orienting Proteomic Discovery Toward Biology and Away from the Measurement Platform (Editorial) Putting the "Bio" Back Into Biomarkers: Orienting Proteomic Discovery Toward Biology and Away from the Measurement Platform (Editorial)

Putting the "Bio" Back Into Biomarkers: Orienting Proteomic Discovery Toward Biology and Away from the Measurement Platform (Editorial‪)‬

Clinical Chemistry, 2008, Jan, 54, 1

    • $5.99
    • $5.99

Publisher Description

The discipline of mass spectrometry (MS)-based serum biomarker profiling is a relatively young field that was launched in a flourish of scientific hope and the clinical promise of a better cancer test (1-5). Nevertheless, the field has already undergone a rollercoaster cycle of optimism and disappointment and renewed enthusiasm during its brief 7-year history (1-8). Before 1999 very little effort was made to directly use MS (MALDI-TOF or ES) as a means to discover new blood biomarkers. Many scientists thought that serum was too complex for MS analysis, and dominated by contaminants, rendering these samples unacceptable for direct introduction into expensive and sophisticated MS research instruments. All of these arguments seemed to be overturned in 1998 when a new class of MALDI-TOF, surface-enhanced laser desorption and ionization (SELDI) was commercialized. Scientists with no formal training in MS saw SELDI as an opportunity to explore the application of MALDI MS to biomarker discovery. Although this method had relatively low resolution, it appeared to provide a fresh, one-step approach to the search for ion signatures of hundreds of candidate biomarkers. Importantly, SELDI-TOF offered a means to support a critical new hypothesis that was emerging in the protein biomarker field. This hypothesis abandoned the assumption that a single specific tumor cell-derived cancer biomarker existed. Instead, cascades of biomarkers were generated from the tumor tissue microenvironment through interactions between the tumor cells and the host cells (e.g., endothelial cells, stroma cells, and immune cells) (1, 5). The tissue-microenvironment hypothesis predicted that a panel of biomarkers could achieve a sensitivity and specificity superior to previous failed cancer biomarker searches (1, 5-8). In 2002 SELDI provided a means for discovering the ion signatures of these putative biomarkers, although their identity was unknown (1, 2).

GENRE
Science & Nature
RELEASED
2008
January 1
LANGUAGE
EN
English
LENGTH
8
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
188.6
KB
Biomarker Discovery and Validation (Editorials) Biomarker Discovery and Validation (Editorials)
2006
SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer (Proteomics and Protein Markers) (Clinical Report) SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer (Proteomics and Protein Markers) (Clinical Report)
2008
Principles of Translational Science in Medicine Principles of Translational Science in Medicine
2021
Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report) Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report)
2001
The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry
2021
Bioinformatics and Biomarker Discovery Bioinformatics and Biomarker Discovery
2011
Genetic Variation in the MTHFR Gene Influences Thiopurine Methyltransferase Activity (Technical Briefs) Genetic Variation in the MTHFR Gene Influences Thiopurine Methyltransferase Activity (Technical Briefs)
2005
C677T and AI298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease (Molecular Diagnostics and Genetics) C677T and AI298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease (Molecular Diagnostics and Genetics)
2001
Ghrelin, Leptin, IGF-1, IGFBP-3, and Insulin Concentrations at Birth: Is There a Relationship with Fetal Growth and Neonatal Anthropometry?(Pediatric Clinical Chemistry) Ghrelin, Leptin, IGF-1, IGFBP-3, and Insulin Concentrations at Birth: Is There a Relationship with Fetal Growth and Neonatal Anthropometry?(Pediatric Clinical Chemistry)
2008
Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial) Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial)
1997
Transferrin Saturation and Screening of Genetic Hemochromatosis (Letters) (Letter to the Editor) Transferrin Saturation and Screening of Genetic Hemochromatosis (Letters) (Letter to the Editor)
1998
Effect of Riboflavin Status on the Homocysteine-Lowering Effect of Folate in Relation to the MTHFR (C677T) Genotype (Nutrition) Effect of Riboflavin Status on the Homocysteine-Lowering Effect of Folate in Relation to the MTHFR (C677T) Genotype (Nutrition)
2003